Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on January 7, 2021, covering events that occurred on January 4, 2021. The company is an emerging growth company incorporated in Delaware with principal executive offices in Alameda, California.
Key Financial Metrics and Obligations
- New Debt: Borrowed an additional $1.0 million under a Secured Convertible Facility Agreement with Juvenescence Limited.
- Repayment Date: The outstanding principal balance is due on March 30, 2023.
- Equity Issuance: Issued unregistered warrants to purchase 328,947 shares of common stock.
- Warrant Terms: Exercise price of $1.52 per share.
- Liquidity and Margins: The filing text does not provide specific values for revenue, profit, cash flow, margins, or total liquidity positions.
Material Changes
The primary material change reported is the increase in debt obligations and the corresponding issuance of equity warrants. This transaction represents a draw on an existing credit facility originally dated March 30, 2020, and amended on July 21, 2020.
Outlook, Risks, and Contingencies
- Events of Default: The loan agreement contains extensive default provisions, including failure to pay within 10 business days, insolvency, cessation of business, or material adverse changes in financial condition.
- Acceleration Clause: Juvenescence may declare the entire outstanding balance immediately due and payable if an Event of Default occurs and remains uncured for 10 business days.
- Collateral and Restrictions: The agreement includes restrictions on asset disposals and requires valid security interests. Default may also be triggered by the loss or destruction of material collateral.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements, noting that actual results may differ materially due to risk factors outlined in periodic reports.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Secured Convertible Facility Agreement following this $1.0 million draw.
- Confirm the listing status of the 328,947 warrants on the NYSE American.
- Review the company's current cash position to assess ability to meet the March 30, 2023 repayment date.
- Examine the Security Agreement to understand the specific assets pledged as collateral.
- Check for any subsequent filings regarding potential Events of Default or covenant breaches.